Floatz logo

Pembrolizumab

Acute Lung Injury

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)monoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Acute Lung Injury cohort.

Asset / SponsorPhaseRating
Pirfenidone
Fujian Medical University Union Hospital
Phase 2CCC
Epirubicin
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
N/AD
Cyclophosphamide
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
N/AD
Carboplatin
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
N/AD

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →